Inovio files for $50M offering amid Covid-19 vaccine hunt; Zydus Cadila signs on with XOMA on IL-2 deal
→ Inovio, the company now building a DNA vaccine against the novel coronavirus, has filed for a $50 million equity offering. Touting its experience bringing a vaccine for MERS — a related virus — into Phase II, Inovio has called itself “the leader in coronavirus vaccines” and, with funding from the Center for Epidemic Preparedness, has said it will have a vaccine in a Phase I human trial in April.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
